


Fédération Française d'Addictologie

www.addictologie.org – @FFAddictologie



COORDINATION
nationale
TDAH
adultes



ALBATROS/WADD Joint Congress 2021 ; symposium proposal.

Abstract title: *updates about the state of care for adult ADHD in France and Europe.*

Chair : Louise CARTON¹, louise.carton@univ-lille.fr

Presentation titles (provisional):

(i) Cross-national disparities in the regulation for ADHD medication in Europe and beyond

Speaker : Mathieu CHAPPUY or Romain ICICK

(ii) ADHD and addictions in France: a challenge to build a multidisciplinary network and improve care context

Speaker : Etienne KAMMERER

(iii) Complex presentation and pharmacotherapy of ADHD with comorbid addiction : a case series

Speaker : Maurice DEMATTEIS or Lucie PENNEL

2. Contact details for all co-authors (alphabetical order):

Mathieu CHAPPUY², mathieu.chappuy@chu-lyon.fr

Maurice DEMATTEIS³, mdematteis@chu-grenoble.fr

Romain ICICK⁴, romain.icick@aphp.fr

Etienne KAMMERER⁵, et.kammerer@wanadoo.fr

Lucie PENNEL³, lpennel@chu-grenoble.fr

Benjamin ROLLAND⁶, benjamin.rolland@ch-le-vinatier.fr

¹University Lille, Inserm U1171 'Degenerative and vascular cognitive disorders', F-59000, Lille, France;

²Hospices Civils de Lyon, Service Universitaire d'Addictologie de Lyon, Lyon, France.

³Addiction medicine, CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France ;

⁴Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Saint-Louis - Lariboisière - Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris F-75010, France;

⁵Fédération Française d'Addictologie, www.addictologie.org, F-75002 Paris, France ;

⁶Centre de Recherche en Neurosciences de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

3. Contact details of the main author who will be the contact for the ALBATROS/WADD Congress:

romain.icick@aphp.fr. CSAPA « Espace Murger », Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, 200 rue du Faubourg Saint-Denis, 75010 Paris, France. Tel: +33140054275 / Fax: +33140054213.

4. Objectives: Precisely describe the objectives of your communication.

Adult attention deficit / hyperactivity disorder (ADHD) is a pervasive neurodevelopmental disorder that affects ~1% children worldwide¹, recently recognized as persistent in adulthood, with a prevalence of 15-20% in special populations such as individuals suffering from addiction². Although centrally-acting psychostimulants are widely and safely used to treat adult ADHD³⁻⁵, none was available in France until very recently⁶, so that patients and health professionals to gather into associations and networks aimed at facilitating proper care and putting pressure on Health authorities. The objective of the current symposium is to provide the audience with an updated and practical overview of ADHD care possibilities in France, notably in the addiction population.

5. Materials and methods

Firstly, Mathieu CHAPPUY / Romain ICICK will describe the **accessibility of psychostimulant drugs for ADHD in adults** in France compared to other countries, using country regulations. Secondly, Etienne KAMMERER will **report aims and achievements from the multidisciplinary group *Coordination Nationale TDAH Adultes***. Thirdly, Lucie PENNEL / Pr. Maurice DEMATTEIS will **describe a series of complex adult ADHD cases and their treatment plan**.

6. Results and conclusions

Two medications show promising advances of availability for adult ADHD in France, although many other countries are more advanced in the field. The *Coordination Nationale TDAH Adultes* was created to face these difficulties, initially focused on addiction populations. Since, it has gathered clinicians from various backgrounds all over France to become actively involved in ADHD care and psychostimulant prescription for adults. In line with recent work from international consortia, our regional case series suggest that psychostimulant medications can be safely used, even at high dosages, after careful ADHD diagnosis and comorbidity assessment, even in case of severe addictions. A national databank could help refining these preliminary findings.

7. Conflicts of interest

BR reports honoraria from HAC pharma and Shire. No other author reports any conflict of interest relevant to ADHD and addiction.

8. References

1. Biederman J, Fitzgerald M, Kirova A-M, Woodworth KY, Biederman I, Faraone SV. Further Evidence of Morbidity and Dysfunction Associated With Subsyndromal ADHD in Clinically Referred Children. *J Clin Psychiatry*. 2018 Aug 7;79(5).
2. Crunelle CL, van den Brink W, Moggi F, Konstenius M, Franck J, Levin FR, et al. International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. *EAR*. 2018;24(1):43-51.
3. Matthijssen A-FM, Dietrich A, Bierens M, Kleine Deters R, van de Loo-Neus GHH, van den Hoofdakker BJ, et al. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study. *AJP*. 2019 May 21;176(9):754-62.
4. Weibel S, Menard O, Ionita A, Boumendjel M, Cabelguen C, Kraemer C, et al. Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults. *Encephale*. 2019 Oct 11;
5. Kooij JJS, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. *European Psychiatry*. 2019 Feb 1;56:14-34.
6. Chappuy M, Boulanger A, Nourredine M, Fournieret P, Rolland B. Disparate regulatory status of methylphenidate for adults with ADHD across Europe. *Lancet Psychiatry*. 2020 Jan;7(1):e1-2.